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http://dx.doi.org/10.1016/j.kjms.201Abstract Radical surgery (RS) with adjuvant chemotherapy (AC) or radiotherapy has been
conventionally used for patients with advanced urothelial carcinoma (AUC). Recent research
has indicated that systemic neoadjuvant chemotherapy (NC) with RS yields better outcomes
than RS alone for patients with locally advanced bladder cancer. However, there are no reports
indicating whether NC or AC would be beneficial for patients with AUC. The present study
compared the survival rate for AUC patients receiving NC or AC. A retrospective analysis was
conducted using data for 64 patients with AUC who underwent RS and systemic chemotherapy
at our institution between March 2002 and March 2011. Of the 64 patients, 30 received NC
before RS and 34 received RS followed by systemic AC. Pathologic stages (pZ 0.002), grades
(pZ 0.018) and lymphovascular invasion (pZ 0.047) were significantly lower in the patients
who received NC first than in those who received RC first. Furthermore, analysis of the surgical
specimens revealed that 26.7% of patients who received NC before RS had complete remission.
There were no significant differences in demographic data, surgical complications, and chemo-
toxicity between the two patient groups. The progression-free survival (PFS) and overall
survival (OS) of patients who received initial NC were significantly better than those of patients
who received initial RC (pZ 0.002 and 0.018, respectively). Our results indicate that NC admin-
istration before RS significantly improved the PFS and OS of AUC patients, without increasingof Urology, Kaohsiung Medical University Hospital, No. 100, Tzyou 1st Road, Kaohsiung 807, Taiwan.
tw (C.-C. Li).
hsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
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Neoadjuvant chemotherapy for advanced UC 201surgical complications and chemotoxicity. Further prospectively controlled trials need to be
conducted to confirm the effectiveness of NC for AUC patients.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Urothelial carcinoma (UC) is a malignant tumor that origi-
nates from the transitional epithelium, including the inner
surface of the upper urinary tract (UUT) and bladder. UC,
the fifth and ninth most common cancer in men and
women, respectively, in the USA, has a variable outcome.
Approximately 70,500 cases of UC were reported in the USA
in 2010; of these, 14,000 individuals died from the disease,
mostly because of progression to advanced UC (AUC) [1,2].
In Taiwan, the rate of UC incidence was 15.4 per 100,000
males in 2008, and the mortality rate associated with UC
has shown an increasing trend [3]. Because UC is a chemo-
sensitive tumor, radical surgery (RS) with adjuvant
chemotherapy (AC) has been conventionally used for
patients with AUC. However, despite new surgical advances
and chemotherapeutic regimens, the overall 5-year survival
rate for patients with AUC has remained relatively
unchanged over recent decades. The 5-year survival rate is
30e50% for pT3 cases and approximately 0e20% for pT4 or
lymph node metastasis cases [4].
Recent studies have evaluated the efficacy of neo-
adjuvant chemotherapy (NC) administered before RS and
AC administered after RS in AUC patients. It has been
speculated that AC increases the recurrence-free survival
rate and improves the outcome for patients with muscle-
invasive bladder cancer; however, not all studies have
shown a survival benefit [5,6]. The effectiveness of NC with
a platinum-based regimen was recently evaluated for
patients with locally advanced bladder cancer. These
studies showed that the survival rates were better for NC
with radical cystectomy than for cystectomy alone [7,8].
However, there are no studies indicating whether NC or AC
would be beneficial for patients with AUC. Hence, the aim
of the present study was to compare the efficacy of NC and
AC in improving the progression-free survival (PFS) and
overall survival (OS) of patients with AUC.
Methods
The study was approved by the Institutional Review Broad
of our hospital. Between March 2002 and March 2011, 101
patients with AUC underwent RS and systemic chemo-
therapy at the Kaohsiung Medical University Hospital,
Kaohsiung Municipal Ta-Tung Hospital, and Kaohsiung
Municipal Hsiao-Kang Hospital. Clinical and histopatholog-
ical data for the patients were retrospectively reviewed.
A smoker was defined as someone who smoked half a pack
of cigarettes per day for more than 6 months. Areas
endemic for blackfoot disease in south Taiwan (Xuejia,
Beimen, Budai, and Yizhu) were included [9].
Patients older than 18 years and who had adequate bone
marrow, liver, and renal functions, and locally advancedcancer (T3 or T4) or lymph node metastasis (N1, N2, or N3)
according to the Response Evaluation Criteria in Solid
Tumors [10] were included in the study. All patients
underwent tumor biopsy to confirm the histopathological
diagnosis. UC diagnosis and staging were confirmed by
independent assessment of all images and specimens by at
least two radiologists and pathologists, respectively. Of the
101 patients, 37 were excluded from the study because of
diffuse metastasis before RS (15 patients), incomplete
chemotherapeutic cycle (10 patients), previous UC (7
patients), a short follow-up period of >3 months (2
patients), or incomplete data (3 patients). The remaining
64 patients were stratified into two groups according to
their treatment strategy. The first group (Group I) received
three cycles of systemic NC before RS. The second group
(Group II) received RS, followed by at least three cycles of
systemic AC. RS included cystectomy with bilateral pelvic
lymphadenectomy for bladder cancer, and nephroureter-
ectomy with bladder cuff excision and retroperitoneal
lymph node dissection for UUT-UC. Various urinary diver-
sions were performed if necessary. RS was performed either
openly or laparoscopically, depending on the choice made
by the patient and the operating surgeons.
All patients received combination chemotherapy
involving a 28-day-cycle gemcitabine and cisplatin regimen:
gemcitabine (1000 mg/m2 body surface area) on Days 1, 8,
and 15; and cisplatin (70 mg/m2) on Day 2 [11]. Before
chemotherapy and in the second week of each chemo-
therapeutic cycle, a complete blood count, serum hepatic
and renal function tests, electrolyte titration, and routine
urine tests were performed. The chemotherapeutic doses
were adjusted if severe toxic effects occurred. Regular
follow-up examinations consisted of interval history and
physical examination, urinalysis, urine cytology, biochem-
ical analysis, chest radiography, abdominal ultrasound, and
abdominal computed tomography. After three cycles of
treatment, chemotherapy responses were assessed
according to clinical information and imaging findings.
Surgical complications and adverse effects of chemo-
therapy were graded according to the severity grading
system of the Memorial Sloan Kettering Cancer Center [12]
and the National Cancer Institute Common Toxicity Criteria
[13], respectively.
PFS was calculated from the date of the initiation of
treatment until the date that UC worsened or recurred. OS
was calculated from the date of the diagnosis of UC until
the date of death or the last contact when the patients
were still alive at the time of follow-up. Demographic and
clinicopathologic characteristics were compared between
groups using the Pearson c2 test or the Student t test. PFS
and OS were calculated according to the KaplaneMeier
method using a log-rank test. Statistical analyses were
performed using JMP v.8.0 (SAS Institute Inc., Cary, NC,
USA) and SPSS v.15.0 (SPSS Inc., Chicago, IL, USA) statistical
202 C.-C. Tsai et al.software. For all statistical analyses, a p value < 0.05 was
considered statistically significant.Results
The median patient age was 66.94 (8.91) years (range
36e82), and the median follow-up period was 21 months
(range 3e58). The demographic characteristics are listed in
Table 1. Of the 64 patients, 30 (47%) underwent NC before
RS (Group I) and 34 (53%) underwent RS followed by AC
(Group II). There were no differences in patient age,
gender, area inhabited, smoking status, and pre-treatment
evaluation between the two groups. With regard to tumor
features, baseline clinical cancer multiplicity, size, loca-
tion, stage, and biopsy grade were also similar (Table 1).
Severe or lethal surgical complications and chemotoxicity
were rare. The Grade 1e3 surgical complication rates,
including extensive blood loss (40% vs. 44%, pZ 0.739),
cardiopulmonary thromboembolism (7% vs. 12%,
pZ 0.480), gastrointestinal adverse effects (17% vs. 24%,
pZ 0.493), nosocomial infection (23% vs. 18%, pZ 0.572),
and poor wound healing (13% vs. 18%, pZ 0.634), were
similar between the two groups (Table 2). The adverse
effects of chemotherapy noted in Groups I and II includedTable 1 Clinical characteristics of the study population.
Characteristic NC before RS
(nZ 30)
Sex
Female 13 (43)
Male 17 (57)
Age (y) 65.30 8.77
BMI (kg/m2) 23.49 3.23
Lived in BFD 10 (33)
Smoking 11 (37)
Pre-treatment data
WBC (103/mL) 7.47 2.33
Hemoglobin (g/dL) 12.90 1.93
Platelets (103/mL) 250.37 70.99
Serum GOT (mg/dL) 26.90 9.04
Serum creatinine (mg/dL) 1.04 0.36
Multiplicity 12 (40)
Tumor size (cm) 4.14 1.84
Tumor location
Upper urinary tract 9 (30)
Bladder 21 (70)
Clinical stage
cTNM Stage 3 10 (33)
cTNM Stage 4 20 (67)
Biopsy grade
High 29 (97)
Low 1 (3)
Chemotherapy response
Positive 23 (77)
Negative 7 (23)
Data are presented as n (%) or mean SD.
ACZ adjuvant chemotherapy; BFDZ blackfoot disease-endemic ar
aminase; NCZ neoadjuvant chemotherapy; RSZ radical surgery; WBgranulocytopenia (27% vs. 38%, pZ 0.323); thrombocyto-
penia (37% vs. 41%, pZ 0.711); anemia (33% vs. 44%,
pZ 0.376), gastrointestinal effects (33% vs. 35%,
pZ 0.869), neuropathy (7% vs. 6%, pZ 0.897), malaise
(23% vs. 41%, pZ 0.126), and hepatotoxicity (43% vs. 26%,
pZ 0.155). None of these differences was statistically
significant. However, nosocomial infections occurred
significantly more frequently in Group II (17% vs. 50%,
pZ 0.042). A particularly noteworthy finding was the
response rate to chemotherapy. Although there was no
significant difference between the two groups, the
response rate to chemotherapy was better in Group I than
in Group II (77% vs. 56%, pZ 0.080; Table 1).
Pathologic features are listed in Table 3. There were
significant reductions in pathologic stage (pZ 0.002) and
grade (pZ 0.018) and lymphovascular invasion (pZ 0.047)
in patients who received NC first. Furthermore, 26.7% of
patients in Group I who had pathologic stage pT0 showed
complete remission (CR), whereas none of the patients in
Group II did. The median follow-up period was 24 months
(range 3e58) and 19 months (range 3e49) for Groups I and
II, respectively. Two patients (3%) were lost to follow-up
and 25 cancer-related deaths (39%) occurred. At the time
of the analysis, 37 patients (58%) remained alive with
regular follow-up. The 2-year PFS rate for Group I and IIAC after RS
(nZ 34)
p
0.315
19 (56)
15 (44)
68.38 8.91 0.169
22.34 5.32 0.306
13 (38) 0.683
13 (38) 0.897
7.38 1.85 0.869
12.19 1.75 0.124
279.32 84.89 0.147
24.65 9.41 0.334
1.03 0.26 0.930
11 (32) 0.525
4.09 2.42 0.924
0.064
18 (53)
16 (47)
17 (50)
17 (50) 0.176
0.928
33 (97)
1 (3)
0.080
19 (56)
15 (44)
ea; BMIZ body mass index; GOTZ glutamic oxaloacetic trans-
CZwhite blood cell count.
p=0.002
Time (Months)
Neoadjuvant chemotherapy
Adjuvant chemotherapy
Figure 1. Progression-free survival for patients with
advanced urothelial carcinoma in the neoadjuvant chemo-
therapy (solid line) and adjuvant chemotherapy (dotted line)
groups (pZ 0.002).
Table 2 Surgical complications and chemotoxicity in
patients receiving neoadjuvant chemotherapy or adjuvant
chemotherapy.
Observation NC before RS
(nZ 30)
AC after RS
(nZ 34)
p
RS complication
Extensive blood loss 12 (40) 15 (44) 0.739
Thromboembolism 2 (7) 4 (12) 0.480
GI adverse effect 5 (17) 8 (24) 0.493
Nosocomial infection 7 (23) 6 (18) 0.572
Poor wound healing 4 (13) 6 (18) 0.634
Chemotherapy toxicity
Granulocytopenia 8 (27) 13 (38) 0.323
Thrombocytopenia 11 (37) 14 (41) 0.711
Anemia 10 (33) 15 (44) 0.376
GI upset 10 (33) 12 (35) 0.869
Neuropathy 2 (7) 2 (6) 0.897
Malaise 7 (23) 14 (41) 0.126
Nosocomial infection 5 (17) 17 (50) 0.042
Hepatotoxicity 13 (43) 9 (26) 0.155
Data are presented as n (%).
ACZ adjuvant chemotherapy; GIZ gastrointestinal;
NCZ neoadjuvant chemotherapy; RSZ radical surgery.
Neoadjuvant chemotherapy for advanced UC 203patients was 63% and 34%, respectively. Additional data
showed that the 2-year OS rate for Group I and II patients
was 72% and 44%, respectively. Our data indicate that
patients who were administered NC before RS had signifi-
cantly better PFS and OS (pZ 0.002 and 0.018, respec-
tively; Figs. 1 and 2).
Discussion
AUC, an incurable terminal disease, accounts for 3% of all
cancer-related mortality in the USA [1]. Conventionally,Table 3 Pathologic characteristics of patients receiving
neoadjuvant chemotherapy or adjuvant chemotherapy.
Observation NC before RS
(nZ 30)
AC after RS
(nZ 34)
p
Pathologic stage 0.002
pTNM  Stage 2 18 (60)a 5 (15)
pTNM  Stage 3 12 (40) 29 (85)
Surgical margin 0.821
Positive 3 (10) 4 (12)
Negative 27 (90) 30 (88)
Grade 0.018
High 20 (67) 33 (97)
Low 10 (33) 1 (3)
LV invasion 0.047
Positive 12 (40) 22 (65)
Negative 18 (60) 12 (35)
Data are presented as n (%).
ACZ adjuvant chemotherapy; LVZ lymphovascular;
NCZ neoadjuvant chemotherapy; RSZ radical surgery.
a Eight cases (26.7%) showed complete remission (pT0).RS has been the mainstay of treatment for AUC for
decades, but the standard has recently been challenged
for many reasons, including the fact that optimal cytore-
ductive surgeries cannot be performed in some patients
and that motility is mainly related to distant spread. With
improvements in therapeutic dose adjustment and inter-
ventions for adverse effects, AC or NC has been recom-
mended for patients with AUC. Although AC after RS is
suggested for patients at high risk of recurrence and
metastasis, there is no clear consensus on the impact of
AC on the survival of AUC patients [5,6]. NC, which causes
adequate tumor shrinkage of unresectable tumors, early
control of metastatic disease, and reduction of occultTime (Months)
Neoadjuvant chemotherapy
Adjuvant chemotherapy
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p=0.018
Figure 2. Overall survival for patients with advanced uro-
thelial carcinoma in the neoadjuvant chemotherapy (solid line)
and adjuvant chemotherapy (dotted line) groups (pZ 0.018).
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choice for AUC patients. However, the use of NC before RS
in AUC patients has not yet been standardized because of
the potential for disease progression from delay of cura-
tive surgery and the increased risk of surgical complica-
tions. Community-based studies have been conducted to
ascertain the beneficial effects of NC for patients with
advanced bladder cancer [7,8,14] and UUT [15]. Few
recent trials have directly compared the efficacy of NC
and AC in patients undergoing RS.
Our results revealed a significant reduction in pathologic
stage in AUC patients who received NC, and these patients
showed a 60% incidence of pT2 or lower disease. Further-
more, of the 30 patients in Group I, 8 (26.7%) were patho-
logically free of cancer (CR, pT0). Grossman et al. observed
a CR rate of 38% in 126 patients with locally advanced
bladder UC who received NC [7]. Matin et al. found that NC
was associated with a 14% CR rate and a significant rate of
downstaging in UUT-UC [15]. A study by Schultz et al.
revealed a CR rate after NC in patients with clinical T2/T3a
of 43%, but only 9% in patients with clinical T3b/T4 tumors
[16]. This is consistent with our finding that more than half
(62.5%) of the CR patients after NC had a lower clinical
stage (cTNM stage 3).
Compared to AC after RS, NC administration before RS
improved PFS and OS for patients with AUC. With regard to
the risk factors for survival, previous studies have revealed
that the primary prognostic factor was pathologic grade
and stage [6,8,17e19]. While low-grade disease was asso-
ciated with a 5-year OS rate that approached 94%, high-
grade disease conferred a poor survival rate of approxi-
mately 28% [20]. Another study conducted at our hospital
showed that the 5-year survival rate was approximately 50%
in UTT-UC patients with pT3 lesions and was less than 5% in
patients with pT4 or node-positive disease [19]. In addition,
pathologic CR was a good surrogate for predicting longer
relapse-free survival and OS. Compared to patients with
residual cancer after NC, those with CR appeared to have
excellent survival rates [8]. This is consistent with our
results indicating that PFS and OS were significantly asso-
ciated with tumor pathologic stages (pZ 0.001 and 0.002)
and grade (pZ 0.004 and 0.012) (data not shown). Lym-
phovascular invasion might be another independent prog-
nostic factor and could be a useful tool during disease
treatment and follow-up [21]. There was a significant
reduction in lymphovascular invasion in Group I patients
who received NC first, and this might have played a role in
the variability of survival between the two groups.
Several mechanisms to explain the impact of NC on
survival have been discussed. Because positive surgical
margins and the lack of optimal RS were found to be
correlated with dismal outcomes [8], NC was considered to
result in adequate tumor shrinkage and better conditions
for optimal RS, leading to better survival results. Another
advantage of NC for survival may be early control of occult
micrometastases. Thoeny et al. observed a high rate of
micrometastases (25%) in urologic cancer patients with
preoperatively negative imaging findings, particularly those
with locally advanced cancer [22]. Current morphologic
assessments conducted using computerized tomography or
magnetic resonance imaging of lymph nodes are based on
size and shape and are unable to detect smaller metastasesin normal-sized nodes [22]. The consequences of missing
micrometastasis are inaccurate preoperative risk stratifi-
cation and treatment strategies, resulting in further distal
metastasis. Since the motility of UC is mainly related to
distant spread, early control of occult micrometastasis in
AUC is considered to play a role in survival improvement.
Besides early tumor control, another plausible reason for
the use of NC, at least for UUT-AUC patients, may be the
strong dose of the cisplatin-based chemotherapy. The
potential risk of nephrotoxicity for a solitary kidney may
discourage oncologists from administering sufficient
cisplatin-based AC after nephroureterectomy. A multifac-
torial analysis by Barlow et al. showed that 52% of patients
who underwent radical nephrectomy for renal cell carci-
noma had new-onset chronic kidney disease more than 3
months after surgery [23]. In our study, there was a trend
towards a poor response rate to chemotherapy in the RS
followed by AC group. This may be attributed to an inad-
equate dose of AC and a delay in the control of distant
spread.
Although the occurrence of myelosuppression or
gastrointestinal effects during chemotherapy was noted in
more than one-third of the patients in our study, all the
patients recovered and there were no life-threatening toxic
effects or deaths. Our study showed that the combination
of gemcitabine and cisplatin can be administered safely
before or after RS to patients with AUC, and this was
because of selection of patients with adequate renal
function, attentive adjustment of drug doses, careful
monitoring of chemotoxicity, and appropriate interventions
for adverse effects. NC did not influence the risk of surgical
complications and did not increase the risk of adverse
effects related to chemotherapy. Nevertheless, a higher
percentage of nosocomial infections was observed for AC,
which may have been caused by unnecessary antibiotic
therapy, prolonged hospital stay, compromised nutritional
or immune status after RS in AUC patients, and decreased
nephron mass and reduced drug excretion after nephrour-
eterectomy in UUT-AUC patients.
There are some limitations to our study. First, the exact
clinical stage of AUC was not confirmed by imaging. A chal-
lenge in NC for AUC lies in accurate preoperative staging.
Predictingwhether patients haveorgan-confinedUCor ahigh
recurrence risk is difficult before RS. Hellenthal et al. re-
ported that uncertainty rates for stage prediction made on
the basis of preoperative imaging and tumor grade at biopsy
and urinary cytologywere approximately 30e40%, and hence
w61% of clinical high-risk AUC patients received NC unnec-
essarily [24]. To identify patients whomight benefit fromNC,
genetic variation [25] and molecular markers are being
investigated for the detection of micrometastases in UC
[26,27]. However, to date, none of themarkers has sufficient
clinical and statistical data to support its validation and to
help clinical decision making. Second, this study was
a retrospective review, and the numbers of UUT-AUC
patients with initial NC were small because of the rare
occurrence. In addition, variability in the techniques used
during RS and the doses used during chemotherapy was
inevitable. Therefore, our empirical results might have
a selection bias. Further randomized, double-blind, multi-
center, and prospectively controlled trials are needed to
clarify the validity of NC for AUC.
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To the best of our knowledge, this study reports on the
largest group of patients with AUC who received NC or AC in
Taiwan, which is one of the areas with the highest rate of
UC incidence. Compared with RS followed by AC, NC
administration before RS increased PFS and OS for patients
with AUC. NC was also associated with a 26.7% CR rate and
significant downstaging of AUC. These results suggest that
NC has a positive impact and might provide strong and
potentially curative cancer control in patients with unre-
sectable AUC. However, more such studies with larger
sample sizes and longer follow-ups are needed to clarify the
role of NC in the therapeutic management of AUC.References
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